Advanced search
Start date
Betweenand

Technical viability evaluation of recombinant vaccine antigens and immunotherapic containing chemokine CCL5 for the control of Salmonella Heidelberg and Salmonella Minnesota infections in commercial poultry

Abstract

Currently, Salmonella enterica is one of the most relevant pathogens for industrial poultry, due to growing concerns about food safety and public health. Brazil is the largest chicken meat exporter in the world and the 2nd largest producer of food of poultry origin. Therefore, this activity has to fulfill many requirements regarding the control of this pathogen. The control of Salmonella enterica infections in birds is performed by several measures of biosafety, antimicrobials, vaccines and alternatives such as probiotics and organic acids. However, a large number of multiresistant antibiotic isolates have spread in the animal production environment and the active ingredients available for use in farm animals have little or no action on them. Most live and inactivated vaccines available in Brazil are licensed to control a few serovars (Salmonella Gallinarum, Salmonella Enteritidis and Salmonella Typhimurium) and there are few available to control emerging serovars such as Salmonella Heidelberg. Thus, new biosecurity tools are extremely relevant in the national and international poultry industry, considering that Brazil is a major player in this economic segment. Thus, this project proposes the evaluation of a vaccine candidate with cross-protective recombinant antigens among the main circulating serovars, associated with a chemokine as an adjunct to mucosal immune response. In addition, the chemokine will be evaluated alone as an immunotherapy, as it attracts leukocytes to the intestinal mucosa and has the potential to reduce the invasive bacterial load in this tissue. In order to adapt the application to the scale of poultry farming, both products will be prepared for oral administration, so that it is administered via feed. Protection against the challenge by Salmonella Heidelberg and S. Minnesota, will be evaluated in vivo, in birds vaccinated or treated with the chemokine CCL5. Thus, this project describes the proposal of two products (a vaccine and an immunotherapeutic) that could be effective as measures of biosecurity for the control of emerging and multidrug-resistant Salmonella serovars. (AU)